The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria

Cancer

Volumn 118, Issue 10, 2012, Pages 2641-2650

  Abogunrin, Funso ^a   O'Kane, Hugh F ^b   Ruddock, Mark W ^c   Stevenson, Michael ^a   Reid, Cherith N ^c   O'Sullivan, Joe M ^a   Anderson, Neil H ^b   O'Rourke, Declan ^b   Duggan, Brian ^b   Lamont, John V ^c   Boyd, Ruth E ^d   Hamilton, Peter ^a   Nambirajan, Thiagarajan ^b   Williamson, Kate E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^c Randox Laboratories Ltd   (United Kingdom)

^d BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

algorithms; biomarkers; CEA; diagnosis; hematuria; protein array analysis; sensitivitity and specificity; urinary bladder neoplasms

Indexed keywords

ANTIHYPERTENSIVE AGENT; BLADDER TUMOR ANTIGEN; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CREATININE; CYTOKERATIN 18; D DIMER; EPIDERMAL GROWTH FACTOR; FAS LIGAND; GELATINASE B; HYALURONIDASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NEURON SPECIFIC ENOLASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NUCLEAR MATRIX PROTEIN 22; THROMBOMODULIN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGE; AGED; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATURIA; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ALGORITHM; PREDICTED PROBABILITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SMOKING; URINE OSMOLALITY;

AGED; ALGORITHMS; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; FEMALE; HEMATURIA; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; PROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84860683069     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26544     Document Type: Article

References (39)

1. Konety BR,. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol. 2006; 24: 326-337.
2. Mostafid H, Persad R, Kockelbergh R, Fawcett D,. Is it time to re-design the haematuria clinic? BJU Int. 2010; 105: 585-588.
3. Shariat SF, Savage C, Chromecki TF, et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer. 2011; 117: 2892-2897.
4. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. standards for reporting of diagnostic accuracy. Clin Chem. 2003; 49: 1-6.
5. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003; 49: 7-18.
6. Cheng ZZ, Corey MJ, Parepalo M, et al. Complement factor H as a marker for detection of bladder cancer. Clin Chem. 2005; 51: 856-863.
7. Lotan Y, Elias K, Svatek RS, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol. 2009; 182: 52-58.
8. Polanski M, Anderson NL,. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights. 2007; 1: 1-48.
9. Margel D, Tal R, Neuman A, Konichezky M, Sella A, Baniel J,. Prediction of extravesical disease by preoperative serum markers in patients with clinically organ confined invasive bladder cancer. J Urol. 2006; 175: 1253-1257.
10. Stieber P, Dienemann H, Hasholzner U, et al. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers. 1994; 9: 82-88.
11. Sanchez-Carbayo M, Urrutia M, Silva JM, Romani R, De Buitrago JM, Navajo JA,. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol. 2001; 165: 1462-1467.
12. Marits P, Karlsson M, Sherif A, Garske U, Thorn M, Winqvist O,. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol. 2006; 49: 59-70.
13. Conticello C, Pedini F, Zeuner A, et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol. 2004; 172: 5467-5477.
14. Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005; 23: 5746-5756.
15. Seddighzadeh M, Larsson P, Ulfgren AC, et al. Low IL-1alpha expression in bladder cancer tissue and survival. Eur Urol. 2003; 43: 362-368.
16. Ahirwar DK, Agrahari A, Mandhani A, Mittal RD,. Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers. 2009; 14: 213-218.
17. Monier F, Mollier S, Guillot M, Rambeaud JJ, Morel F, Zaoui P,. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas. Eur Urol. 2002; 42: 356-363.
18. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P,. Plasma C-reactive protein and risk of cancer: a prospective study from greece. Cancer Epidemiol Biomarkers Prev. 2006; 15: 381-384.
19. Vazquez-Lavista LG, Lima G, Gabilondo F, Llorente L,. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in mexican patients with transitional cell carcinoma of the bladder. Urology. 2009; 74: 414-418.
20. Obama H, Obama K, Takemoto M, et al. Expression of thrombomodulin in the epithelium of the urinary bladder: a possible source of urinary thrombomodulin. Anticancer Res. 1999; 19: 1143-1147.
21. Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar VB,. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res. 2008; 68: 483-491.
22. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL,. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol. 1999; 161: 799-804.
23. Zietek Z, Iwan-Zietek I, Paczulski R, Kotschy M, Wolski Z,. Von willebrand factor antigen in blood plasma of patients with urinary bladder carcinoma. Thromb Res. 1996; 83: 399-402.
24. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM,. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol. 2007; 52: 1388-1396.
25. Roy R, Louis G, Loughlin KR, et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008; 14: 6610-6617.
26. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007; 1: 389-402.
27. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M,. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006; 7: R80.
28. Svatek RS, Herman MP, Lotan Y, et al. Soluble fas-a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer. 2006; 106: 1701-1707.
29. Pisitkun T, Johnstone R, Knepper MA,. Discovery of urinary biomarkers. Mol Cell Proteomics. 2006; 5: 1760-1771.
30. Barratt J, Topham P,. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ. 2007; 177: 361-368.
31. Julian BA, Suzuki H, Suzuki Y, Tomino Y, Spasovski G, Novak J,. Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease. Proteomics Clin Appl. 2009; 3: 1029-1043.
32. Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O,. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem. 2005; 51: 1165-1176.
33. Cohen J,. A coefficient of agreement for nominal scales. Educ Psychol Measure. 1960; 20: 37-46.
34. Feil G, Zumbragel A, Paulgen-Nelde HJ, et al. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder. Anticancer Res. 2003; 23: 963-967.
35. Kramer MW, Escudero DO, Lokeshwar SD, et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer. 2011; 117: 1197-1209.
36. Hu S, Loo JA, Wong DT,. Human body fluid proteome analysis. Proteomics. 2006; 6: 6326-6353.
37. Van de Wouwer M, Collen D, Conway EM,. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004; 24: 1374-1383.
38. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR,. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000; 113 (Pt 23): 4363-4371.
39. Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI,. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int. 2009; 103: 1368-1374.